

Peter Bolli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3581261/publications.pdf>

Version: 2024-02-01

64
papers

5,548
citations

126858

33
h-index

123376

61
g-index

66
all docs

66
docs citations

66
times ranked

4490
citing authors

#	ARTICLE	IF	CITATIONS
1	Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2020, 36, 596-624.	0.8	324
2	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Canadian Journal of Cardiology, 2018, 34, 506-525.	0.8	474
3	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Canadian Journal of Cardiology, 2017, 33, 557-576.	0.8	269
4	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2016, 32, 569-588.	0.8	400
5	The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2015, 31, 549-568.	0.8	431
6	Methods of Assessing blood pressure: identifying threshold and target values (MeasureBP): A Review & Study Protocol. Current Hypertension Reports, 2015, 17, 533.	1.5	4
7	A New Algorithm for the Diagnosis of Hypertension in Canada. Canadian Journal of Cardiology, 2015, 31, 620-630.	0.8	88
8	The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2014, 30, 485-501.	0.8	221
9	Treatment of dyslipidemia: The problem of reaching the goal. Atherosclerosis, 2014, 236, 142-143.	0.4	7
10	The Role of Adiponectin in Endothelial Dysfunction and Hypertension. Current Hypertension Reports, 2014, 16, 463.	1.5	77
11	The 2013 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2013, 29, 528-542.	0.8	163
12	The 2012 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2012, 28, 270-287.	0.8	173
13	Targeting Hypertension in Patients with Cardiorenal Metabolic Syndrome. Current Hypertension Reports, 2012, 14, 397-402.	1.5	4
14	The 2011 Canadian Hypertension Education Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. Canadian Journal of Cardiology, 2011, 27, 415-433.e2.	0.8	127
15	Do Recommendations for the Management of Hypertension Improve Cardiovascular Outcome? The Canadian Experience. International Journal of Hypertension, 2011, 2011, 1-3.	0.5	5
16	Antihypertensive treatment in patients with cerebrovascular disease: the lower the better?. Journal of Hypertension, 2010, 28, 1380-1381.	0.3	1
17	The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I " blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2010, 26, 241-248.	0.8	170
18	The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 " blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2009, 25, 279-286.	0.8	60

#	ARTICLE	IF	CITATIONS
19	The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 – blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2008, 24, 455-463.	0.8	38
20	Treatment Resistant Hypertension. American Journal of Therapeutics, 2008, 15, 351-355.	0.5	6
21	The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 – blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2007, 23, 529-538.	0.8	49
22	High normal blood pressure and prehypertension: The debate continues. Canadian Journal of Cardiology, 2007, 23, 581-583.	0.8	9
23	The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I – Blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2006, 22, 573-581.	0.8	56
24	Masked hypertension: A common but insidious presentation of hypertension. Canadian Journal of Cardiology, 2006, 22, 617-620.	0.8	16
25	The question of the role of ethnicity on cardiovascular risk: does it matter where we come from?. Journal of Hypertension, 2005, 23, 1331-1333.	0.3	4
26	Applying the 2005 Canadian Hypertension Education Program recommendations: 1. Diagnosis of hypertension. Cmaj, 2005, 173, 480-483.	0.9	9
27	New Algorithm for the Diagnosis of Hypertension Canadian Hypertension Education Program Recommendations (2005). American Journal of Hypertension, 2005, 18, 1369-1374.	1.0	57
28	The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2005, 21, 645-56.	0.8	61
29	The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I–Blood pressure measurement, diagnosis and assessment of risk. Canadian Journal of Cardiology, 2004, 20, 31-40.	0.8	38
30	Reducing Cardiovascular Risk with HMG CoA Reductase Inhibitors, Potential Contribution from Platelets. Progress in Experimental Cardiology, 2003, , 107-118.	0.0	0
31	The 2001 Canadian recommendations for the management of hypertension: Part one–Assessment for diagnosis, cardiovascular risk, causes and lifestyle modification. Canadian Journal of Cardiology, 2002, 18, 604-24.	0.8	25
32	Concomitant Digoxin Toxicity and Warfarin Interaction in a Patient Receiving Clarithromycin. Annals of Pharmacotherapy, 1999, 33, 796-799.	0.9	37
33	The Effects of Posture Change and Continuous Positive Airway Pressure on Cardiac Natriuretic Peptides in Congestive Heart Failure. Chest, 1995, 107, 909-915.	0.4	27
34	Serum Lipid Profile Determines Platelet Reactivity to Native and Modified LDL-Cholesterol in Humans. Thrombosis and Haemostasis, 1994, 71, 627-632.	1.8	14
35	Ischemic ECG changes are found more often in asymptomatic men with a coronary prone behaviour pattern. Journal of Psychosomatic Research, 1993, 37, 355-360.	1.2	0
36	Temperature-dependence of LDL binding and activation of human platelets. Thrombosis Research, 1991, 64, 503-508.	0.8	12

#	ARTICLE	IF	CITATIONS
37	Smoking, Antihypertensive Treatment Benefit, and Comprehensive Antihypertensive Treatment Approach. <i>Journal of Cardiovascular Pharmacology</i> , 1990, 16, S77-S80.	0.8	9
38	Adrenaline and Enhanced Vasoconstriction in Patients with Essential Hypertension. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1988, 63, 41-44.	0.0	0
39	Impact of smoking on heart attacks, strokes, blood pressure control, drug dose, and quality of life aspects in the International Prospective Primary Prevention Study in Hypertension. <i>American Heart Journal</i> , 1988, 115, 282-288.	1.2	52
40	Fura-2 used as a probe to show elevated intracellular free calcium in platelets of Dahl-sensitive rats fed a high salt diet. <i>Biochemical and Biophysical Research Communications</i> , 1988, 154, 380-386.	1.0	33
41	Modulation of left ventricular hypertrophy by dietary salt and inhibition of angiotensin converting enzyme. <i>Journal of Hypertension</i> , 1988, 6, S145-147.	0.3	17
42	Calcium antagonism—A New concept for treating essential hypertension. <i>American Journal of Cardiology</i> , 1986, 57, D50-D53.	0.7	23
43	Calcium antagonists and the second drug for hypertensive therapy. <i>American Journal of Medicine</i> , 1986, 81, 25-29.	0.6	47
44	Acute and chronic sympathetic reflex activation and antihypertensive response to nifedipine. <i>Journal of the American College of Cardiology</i> , 1986, 7, 344-348.	1.2	64
45	Atrial Natriuretic Peptide and Atrial Pressure in Patients with Congestive Heart Failure. <i>New England Journal of Medicine</i> , 1986, 315, 533-537.	13.9	622
46	The adrenaline β -adrenoceptor-mediated vasoconstrictor axis. <i>Clinical Science</i> , 1985, 68, 141s-146s.	0.0	8
47	Position of Calcium Antagonists in Antihypertensive Therapy. <i>Journal of Cardiovascular Pharmacology</i> , 1985, 7, S21-S27.	0.8	32
48	Hemodynamic and Antihypertensive Treatment Responses with Calcium Antagonists. <i>Journal of Cardiovascular Pharmacology</i> , 1985, 7, S126-S130.	0.8	7
49	Antihypertensive Treatment Using Calcium Antagonists in Combination with Captopril Rather than Diuretics. <i>Journal of Cardiovascular Pharmacology</i> , 1985, 7, S88-S91.	0.8	72
50	Age, race, blood pressure and renin: Predictors for antihypertensive treatment with calcium antagonists. <i>American Journal of Cardiology</i> , 1985, 56, H81-H85.	0.7	95
51	Correlation of Platelet Calcium with Blood Pressure. <i>New England Journal of Medicine</i> , 1984, 310, 1084-1088.	13.9	556
52	Parallel Reduction of Calcium-Influx-Dependent Vasoconstriction and Platelet-Free Calcium Concentration with Calcium Entry and α -Adrenoceptor Blockade. <i>Journal of Cardiovascular Pharmacology</i> , 1984, 6, S1002.	0.8	43
53	Use of Calcium Antagonists as Monotherapy in the Management of Hypertension. <i>American Journal of Medicine</i> , 1984, 77, 11-15.	0.6	34
54	Renin Profiling to Select Anti hypertensive Baseline Drugs. <i>American Journal of Medicine</i> , 1984, 77, 36-42.	0.6	98

#	ARTICLE	IF	CITATIONS
55	Sympathetic Nervous System in Essential Hypertension and Antihypertensive Response to $\hat{1}\pm 2$ -Adrenoceptor Stimulation. <i>Journal of Cardiovascular Pharmacology</i> , 1984, 6, S753-S756.	0.8	2
56	Verapamil-induced vasodilator response is enhanced in essential hypertension. <i>General Pharmacology</i> , 1983, 14, 185-188.	0.7	1
57	Effects of the Beta-Adrenoceptor-Blocking Agent Sotalol on Ventricular Arrhythmias in Patients with Chronic Ischemic Heart Disease. <i>Cardiology</i> , 1983, 70, 114-121.	0.6	22
58	Role of $\hat{1}\pm$ -Adrenoceptor-Mediated Vasoconstriction for Antihypertensive $\hat{1}2$ -Blockade. <i>Journal of Cardiovascular Pharmacology</i> , 1982, 4, S162-S167.	0.8	12
59	Elevated Adrenaline and Increased $\hat{1}\pm$ -Adrenoceptor-Mediated Vasoconstriction in Essential Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 1982, 4, S134-S138.	0.8	34
60	Greater Antihypertensive Efficacy of the Calcium Channel Inhibitor Verapamil in Older and Low Renin Patients. <i>Clinical Science</i> , 1982, 63, 439s-442s.	0.0	84
61	Changing Role of Beta- and Alpha-Adrenoreceptor-Mediated Cardiovascular Responses in the Transition from High-Cardiac Output into a High-Peripheral Resistance Phase in Essential Hypertension. , 1981, , 316-326.		12
62	Plasma Catecholamines and Cardiac, Renal and Peripheral Vascular Adrenoceptor-Mediated Responses in Different Age Groups of Normal and Hypertensive Subjects. <i>Clinical and Experimental Hypertension</i> , 1980, 2, 409-426.	1.2	62
63	Ticrynafen: Kinetics, protein binding, and effects on serum and urinary uric acid. <i>Clinical Pharmacology and Therapeutics</i> , 1978, 23, 697-702.	2.3	13
64	Effects of prazosin in patients with hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 1976, 20, 138-141.	2.3	33